Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.

Authors: Getter C, Lim YY, Maruff P, Snyder PJ

Journal: Alzheimer's & Dementia

INTRODUCTION: Three 18F-labeled radiopharmaceuticals have been Food and Drug Administration-approved for the identification of cortical amyloidosis in clinical settings. Although there has been strong debate among professionals as to the ethical and social consequences of disclosing […]

Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden.

Authors: Ames D, Burnham SC, Bush AI, Doecke JD, Ellis KA, Macaulay SL, Martins RN, Maruff P, Masters CL, Rembach A, Rowe CC, Villemagne VL, Watt AD, Wilson WJ

Journal: Journal of Alzheimer's Disease

BACKGROUND: We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer’s disease (AD) when coupled to neuroimaging and neuropsychological parameters. METHODS: Participants from the Australian […]

Back to Publications